Paxlovid for the treatment of severe or critical COVID-19 in children
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Paxlovid, known for its efficacy against SARS-CoV-2, is currently limited in its use for treating pediatric COVID-19, particularly in severe or critical cases. Methods We conducted a study within a single-center, prospective cohort of 450 children diagnosed with COVID-19 between December 2022 and May 2023. This study included 30 pediatric patients who received Paxlovid and 60 matched controls who did not, based on factors such as age, disease severity, and underlying health conditions. Safety was assessed through the incidence of adverse events, and laboratory parameters. The time to clinical symptom improvement was the main efficacy outcome. Moreover, we calculated the AUC0 − 12 h of Nirmatrelvir of the Paxlovid patients. Results Adverse events occurred in 16.7% of both groups, with no serious events reported. The Paxlovid group showed a significantly shorter time to viral clearance, fever resolution, and symptom recovery compared to controls (4.9 vs. 11.0 days, P = 0.01; 11.2 vs. 16.4 days, P = 0.01; 4.6 vs. 17.6 days, P < 0.01). This effect was most noticeable in children with underlying conditions or those treated early. No significant differences were observed in ICU transfers or mortality (P > 0.05). The AUC₀-₁₂h of Nirmatrelvir did not significantly alter treatment outcomes. Conclusion Our findings suggest that Paxlovid may be a safe and effective option for treating severe or critical COVID-19 in children.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Paxlovid for the treatment of severe or critical COVID-19 in children
- Date Crossref
- 02/07/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
XinHua Hospital pays non établi dans la noticeÉtablissement de santé
-
Children's Hospital of Zhejiang University pays non établi dans la noticeÉtablissement de santé
-
Shanghai Jiao Tong University Department of Infectious Disease pays non établi dans la noticeUniversité ou école supérieure
-
Wenzhou Medical University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
First Affiliated Hospital of Wenzhou Medical University pays non établi dans la noticeÉtablissement de santé
-
School of Medicine Department of Infectious Disease pays non établi dans la noticeUniversité ou école supérieure
XinHua Hospital, Children's Hospital of Zhejiang University et Department of Infectious Disease — Shanghai Jiao Tong University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.